Abnova (Taiwan) (TPE:4133) NonCurrent Deferred Liabilities: NT$0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4133 Abnova (Taiwan) Corp TPE:4133
75 GF Score
Price NT$22.70
GF Value NT$28.19
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Abnova (Taiwan) NonCurrent Deferred Liabilities?

Abnova (Taiwan) TPE:4133 +4.85% 75 NonCurrent Deferred Liabilities is NT$0.0 Mil as of Dec. 2025. GuruFocus rates TPE:4133 with a GF Score™ of 75/100 and a GF Value™ of NT$28.19 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Abnova (Taiwan)'s non-current deferred liabilities for the quarter that ended in Dec. 2025 was NT$0.0 Mil.

Abnova (Taiwan) NonCurrent Deferred Liabilities Related Terms

Abnova (Taiwan) NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Abnova (Taiwan)'s NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abnova (Taiwan) NonCurrent Deferred Liabilities Chart

Abnova (Taiwan) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Abnova (Taiwan) Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TPE:4133
75GF Score
Abnova (Taiwan) Corp TPE:4133
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of NT$0.0 Mil mean?
Abnova (Taiwan) (TPE:4133) has a NonCurrent Deferred Liabilities of NT$0.0 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Abnova (Taiwan) and its competitors.
Is Abnova (Taiwan)'s NonCurrent Deferred Liabilities too high?
Abnova (Taiwan)'s current NonCurrent Deferred Liabilities is NT$0.0 Mil. Overall, Abnova (Taiwan) has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abnova (Taiwan)'s NonCurrent Deferred Liabilities compare to VRTX and REGN?
Abnova (Taiwan)'s NonCurrent Deferred Liabilities of NT$0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Abnova (Taiwan) and its competitors. Abnova (Taiwan)'s current NonCurrent Deferred Liabilities is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abnova (Taiwan) stock overvalued right now?
Based on GuruFocus' analysis, Abnova (Taiwan) (TPE:4133) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$28.19, compared to a current price of NT$22.70 — trading 19.5% below its estimated fair value. The current NonCurrent Deferred Liabilities is NT$0.0 Mil. Abnova (Taiwan)'s overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Abnova (Taiwan) (TPE:4133), the current NonCurrent Deferred Liabilities is NT$0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abnova (Taiwan) (TPE:4133) Overvalued in 2026?

Based on GuruFocus' analysis, Abnova (Taiwan) stock appears to be undervalued. The current stock price of NT$22.70 is trading 19.5% below its estimated GF Value™ of NT$28.19. GuruFocus considers Abnova (Taiwan) to be Modestly Undervalued.

Key valuation signals for TPE:4133:

  • NonCurrent Deferred Liabilities: NT$0.0 Mil
  • GF Value™: NT$28.19 vs. price of NT$22.70 (19.5% below fair value)
  • GF Score™: 75/100 with 5 warning signs

No single metric tells the full story. See the TPE:4133 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abnova (Taiwan) Business Description

Address No.108, Jhouzih Street, 9th Floor, Neihu District, Taipei City, TWN
Abnova (Taiwan) Corp is engaged in developing, manufacturing, and selling monoclonal antibody, polyclonal antibody, proteins, medical inspection instruments and testing reagents, which are mainly antibody reagents, antibody chips or related products provided to and used by academic, research institutions or pharmaceutical factories. Geographically, it operates in America, Europe, Taiwan and Other Countries. It generates maximum revenue from America. Its products include: SARS-CoV/CoV-2, DNA, RNA new, Proteins/peptides, MaxPab, DNAxPab, Polyclonal Ab, Monoclonal Ab and Others. The company's services are: Gene synthesis & cytogenetics, Peptide services, Protein expression, Humanized antibody, Assay development, Conjugation, FFPE tumor tissue DNA, In situ hybridization (ISH) and Others.
75GF Score

Get the complete analysis for TPE:4133

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$22.70
Price
NT$28.19
GF Value